<DOC>
	<DOCNO>NCT02751151</DOCNO>
	<brief_summary>The study draw patient Transplant Dermatology specialty clinic , investigator see organ transplant recipient ( OTR ) regular screen serve regional referral center population . Enrollment limit 20 patient . Inclusion criterion organ transplant recipient status , active immunosuppression least 5 year , history least one NMSC .</brief_summary>
	<brief_title>Photodynamic Therapy Prevention Nonmelanoma Skin Cancer Organ Transplant Recipients</brief_title>
	<detailed_description>Patients receive Levulan Kerastick ( aminolevulinic acid ) face and/or scalp ( need , treat separately back back day ) ; incubation : 2.5 hour blue light photodynamic therapy utilize DUSA BLU-U device ; illumination : 1000 second ( 16 min , 40 sec ) ; administer quarterly 3 year . Patients change systemic immunosuppression regimen add increase systemic chemoprevention study exclude overall analysis . The patient evaluate principal investigator every 3 month , prior photodynamic therapy ( PDT ) administration . Primary endpoint include : 1. development non melanoma skin cancer ( NMSC ) lesions 2. assessment actinic damage score . The primary endpoint development new skin cancer 3 year , base comparison rate baseline previous ( x ) year ( ) use absolute slope value number prior treatment vs. number treatment . The patient serve control investigator analyze delta development non melanoma skin cancer actinic damage score pre- post- treatment . Additionally , actinic damage score assign base number actinic keratosis initial evaluation . At 3 month follow visit , actinic damage score reassess . The investigator able secondarily analyze delta actinic damage score treatment .</detailed_description>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>1 . The patient recipient solid organ transplant . 2 . Active immunosuppression least 5 year 3 . History least one NMSC 4 . Subject willing sign inform consent participate study . 1 . Patient appropriate candidate treatment research trial per treat physician 2 . Patient mental health condition make unable participate research trial , per PI judgment . 3 . Patient additional immunosuppression diagnosis unrelated organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>